


Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Bhane Y, Qiu X, Cescon DW, Bruce JP,


2016


Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statist Med n/a, 2016.


- South A, Parulekar WR, Sydes MR, Chen BE, Parmar MK, Clarke N, Warde P, Mason M. Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus


2015


- Bartlett JMS, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O’Malley


J, Couban S, MacDonald D, Kukreti V, Kouroukis CT, Baetz T, Szwarzcer D, Desjardins P, Shepherd L, Meyer RM, Le A, Chen BE, Mittmann N, for the Committee on Economic Analysis and the Hematology Disease Site Committee NCTG.


**Journal Publications**
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Péron J, Roy P, Ding K, Parulekar WR, Roche L, Buyse M. Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in


• Eskander A, Merdad M, Irish JC, Hall SF, Groome PA, Freeman JL, Urbach DR,


- Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice. Eur J Can 50: 2303-8, 2014.


2013


- Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase


---


• Dong B, Matthews DE. Empirical Likelihood for Cumulative Hazard Ratio Estimation with

- Jiang S, Tu D. Inference on the probability as a measurement of treatment effect under a density ratio model and random censoring. Computational Statistics and Data Analysis 56: 1069-78, 2012.
Combination with Low Dose Cytarabine (LDAC) In Elderly Patients with AML or High-Risk MDS from the NCIC Clinical Trials Group: Trial IND.186 (ONLINE). Leuk Lymphoma 2012.


2011


- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis IL, Pritchard Ki. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.
- Pritchard Ki, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde


- Sargent D, Shi Q, Yothers G, Van CE, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de GA. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-6, 2011.


- Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E, on behalf of the participants of the 4th Ovarian Cancer
Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2010


Page 33 of 90


- Mackay HJ, Gallinger S, Tsao MS, McLachlin CM, Tu D, Keiser K, Eisenhauer EA, Oza
AM. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Can 46: 1365-73, 2010


- Pujade-Lauraine E, Wagner U, Aavall-Lundquist E, Gebski V, Heywood M, Vasey PA,


- Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J,


2009


- Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: The


- O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant


2008

- Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M,


Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol Oncol 108: 100-5, 2008


Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P, Dancey J, O'Reilly S, Shore T, Couban S, Girouard C, Marlin S, Shepherd L, Pritchard KI. Randomized trial of high-


Dy GK, Kreek JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pockaj BA, Sticca RP, Alberts SR, Pitot


- Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.


2005


- Chen EX, Batist G, Siu LL, Bangash N, MacLean M, McIntosh L, Miller WH Jr, Oza AM,


Lê LH, Moore MJ, Siu LL, Oza AM, MacLean M, Fisher B, Chaudhary A, de Alwis DP,


2005


2004


2003


- Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S,


2002


• Stadler W, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D, Moore M. Long-term survival in phase II trials of gemcitabine plus cisplatin


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2000


1999

- Hospers GAP, Eisenhauer E, de Vries EGE. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications


- Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.


- Zee B, Melnychuck D, Dancey J, Eisenhauer E. Multinomial phase II cancer trials

1998


- Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is


1997

- Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy


- Osoba D, Aaronson N, Zee B, te Velde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.


1996

- Dent S, Eisenhauer E. Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.
- Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenbarg T, Fisher B. Phase II study of the progesterone antagonist mifepristone in patients with untreated


- Piccart M, Raymond E, Aapro M, Eisenhauer E, Cvitkovic E. Cytotoxic agents with


1994

- Mertens W, Eisenhauer E, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced


1992

Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1991


1990

- Blackstein M, Eisenhauer E, Wierzbiicki R, Yoshida S. Epirubicin in extensive small-cell


1989


1988


- Eisenhauer E, Zee B, Pater J, Walsh W. Trimetrexate: Predictors of severe or life-


1987

1986


1985


1984


1980


1979